3 月 9 日，CDE 官网显示，科伦博泰与和铂医药共同申报的 SKB575（HBM7575）注射液获批临床，用于治疗特应性皮炎。来源：CDE 官网公开资料指出，SKB575是一款靶向胸腺基质淋巴细胞生成素（TSLP）及一个未公开靶点的超长效双特异性抗体，凭借独特的分子设计有望显著延长给药周期，提升患者用药依从性，被业界视为具备“全球同类最佳”（Best-in-Class）潜力的重磅品种。此次获批...
Source Link3 月 9 日，CDE 官网显示，科伦博泰与和铂医药共同申报的 SKB575（HBM7575）注射液获批临床，用于治疗特应性皮炎。来源：CDE 官网公开资料指出，SKB575是一款靶向胸腺基质淋巴细胞生成素（TSLP）及一个未公开靶点的超长效双特异性抗体，凭借独特的分子设计有望显著延长给药周期，提升患者用药依从性，被业界视为具备“全球同类最佳”（Best-in-Class）潜力的重磅品种。此次获批...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.